Genomic technology predicts gastric cancer risk

Share This Post

A research team led by the National University Health System (NUHS) and Duke University School of Medicine used genomic technology to better understand intestinal metaplasia (IM), a known risk factor for gastric cancer. Patients with IM are six times more likely to develop gastric cancer than those who do not. This study is an important part of an ambitious investigation to understand why some people develop stomach cancer, while others do not. The study, published in the top cancer research journal Cancer Cell, can also help detect patients infected with H. pylori.

According to statistics from the World Health Organization (WHO), stomach cancer is the third deadliest cancer in the world, with more than 300 deaths each year in Singapore. It is believed that the disease is caused by H. pylori infection, but it can be treated if found early. Unfortunately, more than two-thirds of patients with gastric cancer are diagnosed only at an advanced stage.

Previous genetic research on IM mainly focused on patients who have been diagnosed with gastric cancer, but how to predict the occurrence and development of the patient’s condition is beyond power. This new study is the first to comprehensively map the gene map and can help We better predict the possibility of disease occurrence and development.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy in Mumbai, India
CAR T-Cell therapy

CAR T-Cell therapy in Mumbai, India

CAR T-cell therapy, an advanced cancer treatment, is now available in Mumbai, offering hope to those suffering from some types of blood cancers. This therapy modifies a patient’s T-cells to seek out and destroy cancer cells. It is being offered by many of the leading medical centers in Mumbai, enhancing survival rates and quality of life. With advanced technology and oncologists, Mumbai is slowly becoming a hub for CAR T-cell therapy in India.

LungVax lung cancer vaccine
Lung cancer

LungVax: Lung cancer vaccine

LungVax is an innovative lung cancer vaccine designed to stimulate the immune system to target and destroy cancer cells. It is engineered to enhance the body’s natural defense mechanisms against tumor growth, offering a novel approach to lung cancer treatment. LungVax aims to prevent recurrence in high-risk patients and improve survival rates, marking a promising development in immunotherapy for one of the deadliest forms of cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy